Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin
Pooled result · Composite of cardiovascular death or hospitalization for HFResult — go to the resultOdds ratio 0.66 95% CI 0.48–0.89Authors' conclusion
In conclusion, bexagliflozin, ertugliflozin, and sotagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure.
Study context
- Population
- Patients with T2D in phase 3 or higher RCTs (ClinicalTrials.gov, PubMed, Cochrane CENTRAL, Embase)
- Comparison
- Bexagliflozin, ertugliflozin and sotagliflozin vs placebo and vs each other
- Outcome
- Composite of:
- Cardiovascular death
- Hospitalization for HF
Methodological detailsphase 3 or higher RCTs, random-effects model
- Phase 3 or higher RCTs
- Random-effects model
Pooled result
As reported in the abstract
Odds ratio
0.66
95% CI 0.48–0.89
Bexagliflozin, ertugliflozin and sotagliflozinvs Placebo
OR 0.66 (95% CI 0.48–0.89)
Further pooled results
| Outcome | OR (CI) | |
|---|---|---|
| Hospitalization for HFBexagliflozin, ertugliflozin and sotagliflozinvs Placebo | 0.62 (0.55–0.70) | |
| Acute coronary syndromeBexagliflozin, ertugliflozin and sotagliflozinvs Placebo | 0.35 (0.16–0.77) | |
| MIBexagliflozinvs ErtugliflozinLower risk with bexagliflozin | 0.39 (0.16–0.94) | |
| MISotagliflozinvs ErtugliflozinLower risk with sotagliflozin | 0.41 (0.23–0.72) | |
| 0.10.31310Odds ratio (log scale) |
Original publication
Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin. Diabetes Res Clin Pract. Published 3 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →